Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 10

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 10
---
 with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for                       
 exclusive rights to certain patents and know-how pertaining to WuXi Biologics’ pre-clinical antibody drug conjugate (“ADC”) programs leveraging Hangzhou                                                    
 DAC Biotechnology Co., Ltd.’s (“Hangzhou DAC”) linker-payload technology targeting each of Mucin-16 (“MUC16”), Protein Tyrosine Kinase 7 (“PTK7”) and Seizure Related 6                                     
 Homolog (“SEZ6”) (collectively, the “ADC Programs”).                                                                                                                                                        |

| 3. | Equity Plan Increase Proposal. To approve an amendment to the Aadi Bioscience, Inc. 2021 Equity                                                                                                                       
 Incentive Plan (the “2021 Plan”) to (i) increase the shares available for issuance under the 2021 Plan by 6,300,000 shares from 2,000,284 shares to 8,300,284 shares and (ii) increase the 2021 Plan’s default annual 
 automatic share reserve increase occurring on January 1 of each year from 4% of outstanding shares on the last day of the immediately preceding fiscal year to 5% (the “Equity Plan Increase Proposal”).              |

| 4. | Non-Binding Advisory Vote on Golden Parachutes Proposal. To                                                                                                                                                  
 approve, on a non-binding, advisory basis, certain compensation that will or may become payable to our named executive officers in connection with the Divestiture (the “Non-Binding Advisory Vote on Golden 
 Parachutes Proposal”).                                                                                                                                                                                       |

| 5. | Adjournment Proposal. To approve one or more adjournments of the Special Meeting, if necessary or                                                                                                                                        
 appropriate and to the extent permitted by the Divestiture Agreement, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Divestiture Proposal (the “Adjournment Proposal”). |

As of the date of this proxy statement, we are not aware of any business to come before the Special Meeting other than the five items noted above. - 5 -

How does Aadi’s board of directors recommend that I vote at the Special Meeting? After consideration and consultation with management and its financial and legal advisors, Aadi’s board of directors unanimously recommends that you vote:

| 1. | FOR the Divestiture Proposal; |

| 2. | FOR the PIPE Financing Proposal; |